Skip to content

Effect of different aerobic exercise intensities in patients with chronic heart failure: a randomized controlled trial (HF-EI Study)

Effect of different aerobic exercise intensities in patients with chronic heart failure:a randomized controlled trial (HF-EI Study)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036381
Enrollment
Unknown
Registered
2020-08-22
Start date
2021-04-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

The high-intensity exercise group:Take 70% Peak VO2 as exercise intensity, 3 times a week, 30min each time
Moderate intensity exercise group:The anaerobic metabolism threshold was used as the exercise intensity, 3 times a week, 30min each time

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old; 2. BMI 18-30 kg/m2; 3. LVEF< 0.40; 4. NYHA I~III; 5. Clinical symptoms are stable for at least 2 weeks; 6. The dose of angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist/angiotensin receptor enkephinase inhibitor (ACEI/ARB/ARNI), beta-blocker, aldosterone inhibitor and other drugs was stabilized for at least 2 weeks 7. Agree to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Have a history of heart implant device in the last 6 weeks, or have a recent heart implant device plan or heart transplant plan; 2. Acute coronary syndrome within 6 weeks; 3. Severe valvular heart disease, congenital heart disease, severe hypertrophic obstructive cardiomyopathy, acute myocarditis/pericarditis, intracardiac thrombosis, primary pulmonary hypertension, perinatal cardiomyopathy, thyroid heart disease; 4. Implanted pacemaker with no frequency response function, or set the discharge threshold of ICD lower than the heart rate during exercise; 5. Severe arrhythmias such as ventricular tachycardia, frequent multi-source premature ventricular beats, high atrioventricular block and significant QT interval prolongation occurred during exercise test; 6. Contraindications to exercise training: uncontrolled hypertension (systolic blood pressure >200mmHg and/or diastolic blood pressure >110mmHg); 7. Progressive dyspnea or loss of exercise endurance in the last 3-5 days at rest; 8. Myocardial ischemia under low power exercise load (<2MET, or <50W); 9. Uncontrolled diabetes; 10. Recent embolism; 11.Thrombophlebitis; 12. New atrial fibrillation or atrial flutter, etc., and other conditions not suitable for sports training; 13. Severe liver and kidney dysfunction, liver function more than three times the normal value, eGFR less than 30mL/min/1.73m2; 14. Currently suffering from severe mental illness, severe respiratory disorders, severe hematological diseases, severe nervous and neuromuscular diseases, severe metabolic and endocrine diseases, malignant neoplasms, severe autoimmune diseases, complicated with systemic infections and other acute systemic diseases; 15. Other clinical studies have been included to influence the results of this study; 16. Women who are pregnant or preparing to become pregnant, and women who are breastfeeding; 17. The researchers determined that the patients were not suitable for the study.

Design outcomes

Primary

MeasureTime frame
Peak oxygen uptake;Minnesota Heart Failure Quality of Life Scale;

Secondary

MeasureTime frame
Anaerobic threshold oxygen uptake;Six minutes walking distance;left ventricular ejection fraction;Amino-terminal brain natriuretic peptide (NT-proBNP);Item 9 Patient Health Questionnaire Score (PHQ-9);Generalized Anxiety Disorder Scale score (GAD-7);all-cause mortality;Cardiovascular causes of death;all-cause hospitalization;Hospitalization for heart failure;Major cardiovascular events (MACEs);

Countries

China

Contacts

Public ContactShen YuQin

Shanghai Tongji Hospital

sy_1963@126.com+86 13661615008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026